The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan

被引：0

作者：

Yasuko Asahina

Ayumi Tanaka

Yoshiaki Uyama

Kenji Kuramochi

Hiroshi Maruyama

机构：

[1] Pharmaceuticals and Medical Devices Agency (PMDA),Regulatory Science Research Division, Office of Regulatory Science

[2] Pharmaceuticals and Medical Devices Agency (PMDA),Office of Regulatory Science

[3] Pharmaceuticals and Medical Devices Agency (PMDA),undefined

来源：

Therapeutic Innovation & Regulatory Science | 2013年 / 47卷

关键词：

regulatory science; Japan; drug development; pharmacovigilance; public health; innovation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Recently, it is becoming increasingly difficult to develop innovative drugs. Thus, the role of regulatory science research in drug development and postmarketing settings has become more important. In this article, the authors discuss the roles of regulatory science research at the Pharmaceuticals and Medical Devices Agency (PMDA), which aims to improve public health in Japan.

引用

页码：19 / 22

页数：3

共 50 条

[1] The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan
Asahina, Yasuko
Tanaka, Ayumi
Uyama, Yoshiaki
Kuramochi, Kenji
Maruyama, Hiroshi
[J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (01) : 19 - 22
[2] Regulatory Science in Practice (Pharmaceuticals and Medical Devices Agency)
Hojo, Taisuke
[J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2017, 137 (04): : 439 - 442
[3] Japan Pharmaceuticals and Medical Devices Agency
Nagai, S.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S38 - S38
[4] Future Vision of Regulatory Science in the Global Development of Pharmaceuticals and Medical Devices
Nakamura, Mitsuhiro
Ikeda, Koji
[J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2016, 136 (04): : 523 - 525
[5] Reporting of Cardiovascular Medical Device Adverse Events to Pharmaceuticals and Medical Devices Agency, Japan
Handa, Nobuhiro
Ishii, Kensuke
Matsui, Yutaka
Ando, Yuki
[J]. EBIOMEDICINE, 2015, 2 (09): : 1211 - 1216
[6] Guidelines for clinical evaluation of chronic kidney diseaseAMED research on regulatory science of pharmaceuticals and medical devices
Eiichiro Kanda
Naoki Kashihara
Kunihiro Matsushita
Tomoko Usui
Hirokazu Okada
Kunitoshi Iseki
Kenichi Mikami
Tetsuhiro Tanaka
Takashi Wada
Hirotaka Watada
Kohjiro Ueki
Masaomi Nangaku
[J]. Clinical and Experimental Nephrology, 2018, 22 : 1446 - 1475
[7] The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan
Ishiguro, Chieko
Takeuchi, Yoshinori
Uyama, Yoshiaki
Tawaragi, Tomiko
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (07) : 854 - 859
[8] Practice of Regulatory Science (Development of Medical Devices)
Niimi, Shingo
[J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2017, 137 (04): : 431 - 437
[9] Guidelines for clinical evaluation of chronic kidney disease: AMED research on regulatory science of pharmaceuticals and medical devices
Kanda, Eiichiro
Kashihara, Naoki
Matsushita, Kunihiro
Usui, Tomoko
Okada, Hirokazu
Iseki, Kunitoshi
Mikami, Kenichi
Tanaka, Tetsuhiro
Wada, Takashi
Watada, Hirotaka
Ueki, Kohjiro
Nangaku, Masaomi
[J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (06) : 1446 - 1475
[10] Severe drug eruptions due to lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency
Saeki, Hidehisa
Yamada, Kazuo
Morikawa, Norifumi
Asahina, Akihiko
Ochiai, Toyoko
Iijima, Masafumi
[J]. ALLERGOLOGY INTERNATIONAL, 2017, 66 (01) : 156 - 158

← 1 2 3 4 5 →